IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks

Published on January 7, 2025

Analysts Targets RBC Capital Markets: $61.00 (November 11th, 2024) RBC Capital Markets: $61.00 (September 24th, 2024) RBC Capital Markets:

Continue reading on website
Other news

Nauticus Robotics, Inc. (NASDAQ:KITT) CEO John W. Gibson, Jr. Sells 3,190 Shares

January 7, 2025
64% of Nauticus Robotics as of its most recent SEC filing. Hedge funds and other institutional investors own 20.50% of the company’s stock.

Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year

January 7, 2025
opportunities and making it easier to raise capital for advancing other pipeline candidates. The revenue from taletrectinib could fund